Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma
Protocol ID
DAY101-001 (FIREFLY)
Disease (Sub Disease)
Low-grade Glioma
Diagnosis Stage
Relapse/refractory
Location
NSW, QLD, VIC, WA, SA
Sponsor
Day One Biopharmaceuticals, Inc.
Collaborators
Pacific Pediatric Neuro-Oncology Consortium
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Sydney Children's Hospital
Perth Children's Hospital
The Women's and Children's Hospital
Royal Children's Hospital
Sydney Children's Hospital
Perth Children's Hospital
The Women's and Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
6 Months to 25 Years
International registry ID's
NCT04775485
| Study Title | A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma |
|---|---|
| Protocol ID | DAY101-001 (FIREFLY) |
| Disease (Sub Disease) | Low-grade Glioma |
| Diagnosis Stage | Relapse/refractory |
| Location | NSW / QLD / VIC / WA / SA |
| Sponsor | Day One Biopharmaceuticals, Inc. |
| Collaborators | Pacific Pediatric Neuro-Oncology Consortium |
| Links | https://clinicaltrials.gov/ct2/show/NCT04775485 |
| Trial Status | Open |
| Trial Open Date | 17/03/2021 |
| Sites | Queensland Children's Hospital / Sydney Children's Hospital / Perth Children's Hospital / The Women's and Children's Hospital/ Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 6 Months to 25 Years |
| International registry ID's | NCT04775485 |